Subscribe now
23andMe's breast cancer test may create false sense of security

23andMe's breast cancer test may create false sense of security

7 March 2018

Genomics firm 23andMe is the first to receive approval for direct-to-consumer cancer gene tests in the US, but will recipients misunderstand the results?

Sign up to our weekly newsletter

Receive a weekly dose of discovery in your inbox. We'll also keep you up to date with New Scientist events and special offers.

Sign up
Piano Exit Overlay Banner Mobile Piano Exit Overlay Banner Desktop